Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. - Wikidata - wikimedia - TriplyDB

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

http://www.wikidata.org/entity/Q50769076

about

Genetic selection for protein solubility enabled by the folding quality control feature of the twin-arginine translocation pathway.T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.NY-ESO-1 immunotherapy for multiple myeloma.Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.PEGylation and its impact on the design of new protein-based medicines.NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.Inducing efficient cross-priming using antigen-coated yeast particles.Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.Detection and expression analysis of recombinant proteins in plant-derived complex mixtures using nanoUPLC-MS(E).Vaccine and immune cell therapy in non-small cell lung cancer.Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma

P2860

Q33232877-9BCFF798-B7A6-4861-956C-9CF8180A06AE Q34111757-50FF9386-E9F7-430C-80BE-4E3A7940DD6A Q34412732-74EDD662-3088-478B-8477-E4960F469758 Q34627677-E0AC7144-FFC6-44D7-AD68-2A812F5CF67D Q36637651-8E82AF59-A778-4CF8-B708-B3E9868E8E1F Q37762274-AEB2D9B0-BE97-49F0-AE76-040DC4B4A50D Q38269324-ED5C103A-2CD6-4C00-9D99-CEF13191D333 Q39150340-EA41C53A-6C0D-4470-97BA-1181C4D06FF2 Q41822345-F2869AD1-187B-4894-9098-371CAC85BAF1 Q44545688-230C62B4-5CB9-4047-886E-6CE3C6BB4A0D Q44916488-C7E324F1-A67D-4EBF-90D8-54F0C6EB4D27 Q55284807-51DFD6D6-A888-4644-AF8D-F2376844E714 Q57571845-62C49261-EF87-4E05-B223-9FB94503583C

P2860

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

http://www.wikidata.org/entity/Q50769076

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

@en

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

@nl

type

label

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

@en

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

@nl

prefLabel

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

@en

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

@nl

P1433

Q50769076-AF19263C-BB7D-47BD-9075-463916D8400E

P1476

Q50769076-D5E4BEE8-74FD-4B4B-B580-1572268FAEFE

P2093

Q50769076-02965D88-4DAA-40C7-BC8A-998152E171EE

Q50769076-0948E6E8-A0B0-4B0A-BE3B-423A28828723

Q50769076-0AC3D574-74EE-4D63-9B87-310993794913

Q50769076-2BC6678C-7B0E-41EC-97E5-617F22C600DF

Q50769076-39D13954-295D-4D62-A91B-8C03252580E7

Q50769076-3A1A3366-3777-40FF-8AC0-6111DD3D2CD5

Q50769076-3D437F4C-FB20-40A5-AD17-592194372AC8

Q50769076-4150FB9F-6E0C-4415-B496-D52FE8ED2853

Q50769076-5532E4D9-3643-4033-B7D0-2A03933BAE3D

Q50769076-56EC9368-CBA1-4148-BCEE-B825B2349024

P2860

Q50769076-15114582-4ADC-4D58-900F-8D86946DA374

Q50769076-1F17735D-BA39-4C81-B11E-A030E136113E

Q50769076-2CE5ED49-DD7C-4E01-8F1B-136D479FFEB9

Q50769076-31EF0B1A-ABC0-4929-BB24-38F6966D4388

Q50769076-39242E06-C920-4685-93A6-FC390C4010E9

Q50769076-4E527EBF-FAB5-4166-83D7-C5CDAC6841A1

Q50769076-513528CF-1414-4D30-96F9-1FE44AB41C71

Q50769076-536E19C1-43A5-4DEA-8352-A12EBF82E75A

Q50769076-76F860F3-C6A0-444F-A30D-B9795B2E1B29

Q50769076-8A977C60-C6F3-41D4-A601-4F8169BFF9D0

P304

Q50769076-8AAF7FEC-59C5-49E5-842A-4BF66F6B28AD

P31

Q50769076-C457B727-3752-4074-A7CB-2F1BEFFD7B26

P356

Q50769076-12C07685-5D56-44B3-A91A-92FEA56B5F17

P433

Q50769076-2AAC92C1-6A67-495F-834C-77A44D062657

P478

Q50769076-625AAC06-6555-4BF4-9B51-7C6B20A558AC

P577

Q50769076-387E763A-4595-4962-AD8D-18206EAF83A3

P698

Q50769076-F1ADDBBF-95DF-4EFC-8EDE-4359DA34A500

P356

P1433

Preparative Biochemistry and Biotechnology

P1476

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

@en

P2093

Ackland J

http://www.w3.org/2001/XMLSchema#string

Cartwright G

http://www.w3.org/2001/XMLSchema#string

Cebon J

http://www.w3.org/2001/XMLSchema#string

Chen YT

http://www.w3.org/2001/XMLSchema#string

Cohen L

http://www.w3.org/2001/XMLSchema#string

Davis ID

http://www.w3.org/2001/XMLSchema#string

Dumsday G

http://www.w3.org/2001/XMLSchema#string

Green S

http://www.w3.org/2001/XMLSchema#string

Healey K

http://www.w3.org/2001/XMLSchema#string

Hoffman EW

http://www.w3.org/2001/XMLSchema#string

P2860

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Immunology and immunotherapy of human cancer: present concepts and clinical developments.

Anti-idiotype vaccine against cancer.

Progress in the development of immunotherapy for the treatment of patients with cancer.

Rational approaches to human cancer immunotherapy.

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

P304

119-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1081/PB-200054732

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15881594

http://www.w3.org/2001/XMLSchema#string